Olon Expands API Powerhouse With HuvePharma Italia Acquisition

Olon, a global leader in chemical-pharmaceutical manufacturing, has unveiled its intention to acquire HuvePharma Italia Srl, along with its production facility located in Garessio, Cuneo, Italy. The acquisition aims to fully integrate HuvePharma Italia Srl into Olon's operations, with a strategic plan to rejuvenate the Garessio plant and boost its production capacity. Through new business ventures, the facility is set to reach full operational output. 

This marks Olon's ninth manufacturing site in Italy, enhancing its total reaction capacity to 3,250 cubic meters. HuvePharma Italia Srl specializes in the development, industrialization, chemical synthesis, and commercialization of active pharmaceutical ingredients (APIs) and advanced intermediates. With a strong presence in the pharmaceutical chemical industry, the company brings vast expertise in API production and is adept at incorporating new technological advancements.

From the beginning, Olon Group has focused on growth, consolidation, and global expansion, leveraging both internal development and external acquisitions. This latest deal is set to enhance and diversify Olon’s product range, particularly in key strategic sectors. Acquiring Huvepharma Italia marks a major advancement in increasing their production capabilities. The strategy includes a comprehensive integration of all Huvepharma Italia’s assets—its facilities, team, and product offerings—to fully capitalize on their potential.

Paolo Tubertini, CEO of Olon Group, said “We recognized in Huvepharma Italia all the right characteristics. The acquisition supports the implementation of the Group's medium to long term strategy and the achievement of our business objectives. We will capitalize on the integration with Olon's existing manufacturing network, which already includes 12 sites worldwide and 7 integrated and interconnected research centers, with our consolidated customer portfolio, which includes all the major pharmaceutical companies in the market, and our solid reputation as a partner and API supplier. The objective of the transaction is to significantly increase our overall API production capacity by unlocking the potential of the Garessio site.”